Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Xenotransplantation of human adipose derived mesenchymal stem cells in a rodent model of Huntington's disease: motor and non-motor outcomes.

Hosseini M., Moghadas M., Edalatmanesh MA., Hashemzadeh MR.

Animal Study on Neuroinflammation, published in Neurol Res (2014) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Neurol Res (2014)
Country
England
Reported sample size
—
Source database
PubMed
PMID
25376132
DOI
10.1179/1743132814Y.0000000456
Citations
11

Abstract (original English)

Human mesenchymal stem cells (hMSCs) have been presented as alternative sources of cells to be transplanted into the brain in neurodegenerative disorders. In this regard, the efficacy of hMSCs transplants in reducing motor and non-motor deficits in a quinolinic acid (QA) rat model of Huntington's disease (HD) was tested in the present study. After unilateral lesions in striatum by QA, the isolated and purified hMSCs from liposuction of healthy male donors were transplanted into the damaged striatum of the rats. The cells were stably transfected with a vector containing TurboGFP and JRed to make it possible to trace them after transplantation. Animals were tested by motor and non-motor function tests at different times after the cell transplantation. The hMSCs survived 7 weeks in the brains. An improvement was observed in behavioral tests such as apomophine-induced rotation, hanging wire, and rotarod for the hMSC-treated rats. Anxiety like behaviors were decreased in hMSCs-treated animals when they were examined using open field, elevated plus maze, light and dark box, and novelty suppressed feeding tests. Compared to QA, the hMSCs treatment decreased motor activities. These results confirmed the potential efficacy of hMSCs in treatment of behavioral defects in HD. Generally, the data demonstrated that xenologous transplantation of hMSCs could be considered as an ideal candidate

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Adipose TissueAnimalsAnxietyCorpus StriatumDisease Models, AnimalHumansHuntington DiseaseMaleMesenchymal Stem Cell TransplantationMesenchymal Stem Cells

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research